Judd Jessup has been named CEO of CombiMatrix, the firm said this week. Judd will take over the company's top position from interim CEO Mark McGowan, effective Aug. 23. Upon stepping down, McGowan will continue his duties as chairman of the firm's board of directors.
Jessup most recently was CEO of US Labs, a cancer diagnostic and genetic testing services lab. He also previously served as president of the Health Plans Division for FHP International as well as the president of publicly traded HMO TakeCare. Jessup currently serves on the boards of Corvel and NovaMed.
According to a filing with the US Securities and Exchange Commission, Jessup will be paid a base salary of $420,000 per year and, subject to board approval, an annual performance bonus. Jessup was also granted a stock option to purchase 400,000 shares of CombiMatrix's common stock at an exercise price of $2.74 per share. The stock option vests over four years.
NanoInk this week appointed Oliver Yeh as the general manager of sales for the Asia-Pacific region and Robert Marchmont as the general manager for Europe, the Middle East, and Africa.
Yeh previously was the vice president and general manager at Veeco Instruments in Taiwan. Prior to that, he worked as the senior account sales manager for Lam Research, also in Taiwan. Yeh holds a BS in chemistry from Tung-Hai University and an MS in chemical oceanography from Old Dominion University.
Marchmont previously was the CEO at TotalLab in the UK. He was also the European business director for Protein Forest, and served as global marketing director for GE Healthcare's Life Science Division. Marchmont holds a BS in biochemistry and a PhD in membrane biochemistry from the University of Manchester Institute of Science & Technology.
Kreatech Diagnostics last week named Rolf Hansen as director of marketing and sales. Hansen has worked for Qiagen, Beckman Coulter, Miltenyi Biotech, and Transgenomic, and holds a PhD in natural science from the Max Planck Institute.